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This viewpoint review provides an integrative picture of seemingly contradictory work 
published on N-methyl-d-aspartate receptor 1 (NMDAR1) autoantibodies (AB). Based on 
the present state of knowledge, it gives recommendations for the clinical decision pro-
cess regarding immunosuppressive treatment. Brain antigen-directed AB in general and 
NMDAR1-AB in particular belong to a preexisting autoimmune repertoire of mammals 
including humans. Specific autoimmune reactive B cells may get repeatedly (perhaps 
transiently) boosted by various potential stimulants (e.g., microbiome, infections, or 
neoplasms) plus less efficiently suppressed over lifespan (gradual loss of tolerance), likely 
explaining the increasing seroprevalence upon aging (>20% NMDAR1-AB in 80-year-
old humans). Pathophysiological significance emerges (I) when AB-specific plasma cells 
settle in the brain and produce large amounts of brain antigen-directed AB intrathecally 
and/or (II) in conditions of compromised blood–brain barrier (BBB), for instance, upon 
injury, infection, inflammation, or genetic predisposition (APOE4 haplotype), which then 
allows substantial access of circulating AB to the brain. Regarding NMDAR1-AB, func-
tional effects on neurons in  vitro and elicitation of brain symptoms in  vivo have been 
demonstrated for immunoglobulin (Ig) classes, IgM, IgA, and IgG. Under conditions of 
brain inflammation, intrathecal production and class switch to IgG may provoke high 
NMDAR1-AB (and other brain antigen-directed AB) levels in cerebrospinal fluid (CSF) 
and serum, causing the severe syndrome named “anti-NMDAR encephalitis,” which 
then requires immunosuppressive therapy on top of the causal encephalitis treatment (if 
available). However, negative CSF NMDAR1-AB results cannot exclude chronic effects 
of serum NMDAR1-AB on the central nervous system, since the brain acts as “immu-
noprecipitator,” particularly in situations of compromised BBB. In any case of suspected 
symptomatic consequences of circulating AB directed against brain antigens, leakiness 
of the BBB should be evaluated by CSF analysis (albumin quotient as proxy) and mag-
netic resonance imaging before considering immunosuppression.
Keywords: blood–brain barrier dysfunction, immunoglobulin class, serum, cerebrospinal fluid, inflammation, 
functionality assays, neuropsychiatric diseases, healthy subjects
FiGURe 1 | integration of nMDAR1 autoantibodies (AB) findings into 
an explanatory model.
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This viewpoint review is arranged around two tabulated figures, 
one summarizing NMDAR1 autoantibody (AB) findings and 
integrating them into an explanatory model (Figure  1) and 
the other trying to give clear recommendations for the clinical 
decision process on immunosuppressive treatment based on the 
present state of knowledge (Figure 2).
Please note that the new nomenclature GluN1 for NMDAR1/
NR1 is disregarded here for consistency with most of the respec-
tive reviewed literature.
nMDA ReCePTORS in BRAin AnD 
PeRiPHeRY
N-methyl-d-aspartate receptors (NMDAR) are glutamate-gated 
ion channels, abundantly expressed in mammalian brain (1). 
They form heteromers of NR1, NR2, and NR3 subunits, with 
NR1 being the only obligatory partner. NMDAR are pivotal for 
regulating neuronal/synapse function and are also expressed 
by non-neuronal cell types in the brain like astrocytes, oligo-
dendrocytes, or endothelial cells (2–5). In addition, peripheral 
expression has been reported, e.g., in the gastrointestinal tract or 
in immune cells (6).
AnTi-nMDAR enCePHALiTiS
Autoantibodies of the immunoglobulin G (IgG) class directed 
against NMDAR1 have been originally linked with a condition 
named “anti-NMDAR encephalitis” (7–10). In 2007, Dalmau and 
colleagues first described a paraneoplastic syndrome, based on 12 
women with ovarian teratoma, carrying IgG AB against NMDAR 
NR1/2 subunits. The syndrome variably consisted of psychosis, 
cognitive decline, epileptic seizures, dyskinesia, decreased 
consciousness, and autonomic instability. The authors reported 
in many subsequent publications, based on increasing numbers 
of individuals with anti-NMDAR encephalitis, high serum and 
cerebrospinal fluid (CSF) titers of NMDAR1-AB of the IgG 
class in this condition as well as frequently favorable response 
to immunosuppressive therapy (7–10). As syndrome-pertinent 
pathophysiological mechanism, NMDAR1-AB induced decrease 
of NMDAR-mediated currents, due to enhanced receptor 
internalization, and thus reduced surface expression, has been 
suggested (11). However, over several years, healthy subjects were 
not even investigated in appreciable numbers for NMDAR1-AB 
seroprevalence. Nevertheless, the presence of NMDAR1-AB of 
the IgG class in serum (not only in CSF) was and still is claimed 
to be disease specific (7–10), causing some confusion in the 
literature and unfortunately also in clinical practice.
SYnDROMeS ReMiniSCenT OF nMDAR1 
AnTAGOniSM
Since NMDAR hypofunction had been hypothesized to be 
a central mechanism in schizophrenia, due to induction of 
psychotic symptoms by antagonists (12, 13), the question arose 
several years ago whether a subpopulation of schizophrenic 
subjects may be previously overlooked anti-NMDAR encepha-
litis cases. So far, the literature—mostly based on small sample 
sizes and following the original “disease-specificity claim of 
NMDAR1-AB of the IgG class”—yielded discordant results 
(14–20). Analogously, other pathological conditions, likewise 
reminiscent of NMDAR antagonism, e.g., epilepsy or dementia, 
were investigated for the presence of NMDAR1-AB. A flood of 
publications appeared—many of them case reports—describing 
associations of NMDAR1-AB with a wide variety of syndromes. 
Finally, NMDAR1-AB of other immunoglobulin (Ig) classes 
(IgM and IgA) were also reported to be associated with dis-
ease conditions (17, 21–23). An interesting question that has 
remained totally open up to now is whether NMDAR1-AB can 
also lead to “peripheral phenotypes,” considering the expression 
of NMDAR in peripheral organs and tissues (6).
eQUAL DiSTRiBUTiOn OF SeRUM 
nMDAR1-AB ACROSS HeALTH AnD 
DiSeASe
Unexpectedly, recent work of us and others on together >5,000 
individuals challenged the “disease-specificity claim” of any 
FiGURe 2 | Recommendations for the clinical decision process.
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NMDAR1-AB by demonstrating age dependent up to >20% 
NMDAR1-AB seroprevalence, including IgM, IgA, and IgG, in 
both healthy and ill subjects. Interestingly, NMDAR1-AB of the 
IgE class were searched for but never detected (24). Diseases 
investigated in these studies comprise neuropsychiatric condi-
tions (schizophrenia, affective disorders, Parkinson’s disease, 
amyotrophic lateral sclerosis, Alzheimer’s disease, stroke, 
multiple sclerosis, and personality disorders) as well as general 
medical conditions, e.g., diabetes or hypertension (24–28). Also 
NMDAR1-AB titer range in serum and the distribution of Ig 
classes were comparable across all investigated disease groups 
as well as healthy individuals (24–28). Any 40-year-old person 
has a ~10% and any 80-year-old person has a ~20% chance of 
displaying NMDAR1-AB seropositivity (24).
FUnCTiOnALiTY OF nMDAR1-AB
This surprising discovery raised the question of whether these AB 
are all functional. Since biochip mosaics and a cell-based assay, 
the clinical standard procedure (HEK293T-cells transfected 
with NMDAR1 and secondary AB against human IgG, IgM, or 
IgA; Euroimmun, Lübeck, Germany), were used for all of these 
NMDAR1-AB determinations (see also below), additional assays 
had to be performed to further consolidate these unanticipated 
findings by proving AB functionality. These in  vitro assays (all 
conducted with sera following ammonium sulfate precipita-
tion of immunoglobulins and dialysis) revealed similar effects 
of NMDAR1-AB—independent of the Ig class—on receptor 
internalization in human IPSC-derived neurons as well as in 
primary mouse neurons. Likewise, NMDAR1-AB of all Ig classes 
reduced glutamate-evoked currents in NR1-1b/NR2A expressing 
Xenopus laevis oocytes (26, 28, 29). In vivo studies in mouse and 
human suggest comparable effects of serum NMDAR1-AB of 
all Ig classes regarding modulation of brain functions (see more 
details below).
MeTHODS OF AB DeTeCTiOn—STiLL 
ROOM FOR iMPROveMenT
A still pending problem calling for standardization is the diversity 
of methods applied for AB determination with different speci-
ficity and sensitivity. Regarding NMDAR1-AB (where we have 
the most solid own experience), cell-based assays are certainly 
the superior method to detect NMDAR1-AB since epitopes are 
exposed in a natural way to enable AB to specifically detect them. 
But even these assays differ, with some authors using transiently 
transfected live cells accepting their potential variability and 
batch-to-batch variation problems, versus others using fixed and 
permeabilized cells expressing the whole NMDAR1 subunit, 
likely allowing better standardization (Euroimmun). This latter 
assay is currently being used throughout the world to diagnose 
NMDAR1-AB encephalitis. Based on our own experience with 
this assay in association with functionality studies performed in 
parallel (receptor internalization, electrophysiology, and in vivo 
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studies), it appears to be the most reliable method at this point. It 
is, however, strongly recommended to use this assay in combina-
tion with secondary AB that are highly specific for the various Ig 
classes (anti-human IgG, anti-human IgA, and anti-human IgM) 
since cross-reacting AB may lead to wrong conclusions regard-
ing, e.g., the prevalence of IgG AB. The use of rat, mouse, human, 
or monkey brain sections for immunohistochemical detection 
of specific AB may be a helpful addition providing supportive 
evidence. In contrast, the typical ELISA based on peptides can-
not be recommended as a detection method for NMDAR1-AB, 
since many false-positive and/or false-negative results may be 
obtained due to the unnatural (removed from the position in 
the cell membrane) epitope exposure. These assays seem only 
suitable for follow-up analyses, for instance, the determination 
of the AB titer course using a series of samples from the same 
donor, previously clearly diagnosed as seropositive by cell-based 
and functional assays.
A DeCiSive ROLe OF THe BLOOD–BRAin 
BARRieR (BBB) FOR SYnDROMiC 
ReLevAnCe
Wondering why so many serum NMDAR1-AB carriers remain 
healthy, we hypothesized that a compromised BBB might decide 
on their pathophysiological significance. Importantly, enhanced 
BBB permeability may differ regionally, thereby explaining indi-
vidually variable symptomatic consequences (30). As an animal 
model, we studied ApoE−/− mice with known BBB leakage in 
comparison to wild-type littermates (31). Intravenous injection 
of purified Ig fractions from NMDAR-AB seropositive (IgM, IgG, 
and IgA) human subjects led to alterations in spontaneous open 
field activity and hypersensitive (psychosis related) response 
to MK-801 in the open field exclusively in ApoE−/− mice (28). 
Exploring the role of a compromised BBB subsequently also in 
humans, we saw indeed more severe neurological symptoms in 
NMDAR1-AB carriers (of any Ig class) with a history of birth 
complications or neurotrauma, conditions with likely chronically 
leaky BBB (28). Along the same lines, we investigated APOE4 
carriers since the APOE4 haplotype has been associated with a 
permeable BBB (32, 33). We obtained first hints that NMDAR-AB 
may enhance delusions of grandiosity and mania in neuropsychi-
atrically ill APOE4 carriers, which are then more likely diagnosed 
schizoaffective (29). A modifier role of preexisting circulating 
NMDAR1-AB (again of all classes) was also seen in human 
ischemic stroke. In patients with intact BBB before occurrence of 
the insult, NMDAR1-AB were protective with respect to evolu-
tion of lesion size, whereas in APOE4 carriers, NMDAR1-AB 
were associated with larger insult volumes (24). These findings 
emphasize that not only degree but also duration of BBB dysfunc-
tion, acute versus chronic, may play a pivotal role in syndrome 
shaping by NMDAR1-AB.
THe BRAin AS iMMUnOPReCiPiTATOR 
OF nMDAR1-AB
Circulating NMDAR1-AB of all Ig isotypes temporarily 
decreased after stroke (24). This led us hypothesize that 
brain tissue with its densely expressed NMDAR1 (acces-
sible after BBB breakdown) may act as a trap for circulating 
NMDAR1-AB (25). We first addressed the question of whether 
serum NMDAR1-AB would be detectable in the CSF. Of 
N  =  271 middle-aged subjects (diagnosed with multiple 
sclerosis or disease controls) with CSF–serum pairs available, 
26 were NMDAR1-AB seropositive (which is in the expected 
range) but, remarkably, only 1 was CSF positive. In contrast, 
tetanus-AB (omnipresent due to obligatory vaccination but 
not binding to brain tissue) were present in serum and CSF 
of all subjects, with CSF levels higher upon compromised 
BBB. Translational experiments in mice proved the hypothesis 
that the brain acts as “immunoprecipitator”: simultaneous 
injection of NMDAR1-AB IgG and a non-brain-binding “non-
sense-AB” (anti-GFP IgG) resulted in high detectability of the 
former only in the brain (distinctly more pronounced upon 
BBB dysfunction) and the latter only in CSF (25). These data 
may help explaining potential symptomatic consequences of 
serum AB directed against brain antigens. Whereas leakiness 
of the BBB has a major role and should be evaluated in cases 
where pathological relevance of circulating NMDAR1-AB is 
suspected, negative results regarding AB titers in CSF cannot 
automatically exclude brain effects.
ePiTOPeS ReCOGniZeD BY nMDAR1-AB
The next question was whether these apparently overall functional 
NMDAR1-AB would recognize the same epitope and whether 
this could potentially explain their high seroprevalence. Again 
unexpectedly, epitope mapping using seven different NMDAR1 
constructs revealed recognition by NMDAR1-AB-positive sera 
of different epitopes, located in the extracellular ligand binding 
and the N-terminal domain (NTD) as well as the intracellular 
C-terminal and the extra large pore domain. NMDAR1-AB sero-
positivity was polyclonal/polyspecific in half of the investigated 
sera and likely mono or oligoclonal/oligospecific (mainly IgG) 
in the other half. Overall, no particular disease-related pattern 
appeared: NMDAR1 epitopes were comparable across disease 
groups (26). Published work on NMDAR1-AB epitopes has been 
scarce before this systematic investigation and had focused on 
IgG recognizing NTD and the NTD-G7 domain (N368/G369), 
probably because this region and Ig class were first deemed 
pathognomonic for anti-NMDAR encephalitis (8, 34). Indeed, it 
seems that factors predisposing young women [including those 
with ovarian teratoma and with lupus erythematosus (35)] to 
neuropsychiatric manifestations of NMDAR1-associated auto-
immunity are connected with NTD or NTD-G7 epitopes. The 
accentuated role of IgG in this context is still a matter of specula-
tion but likely related to inflammation-induced class switch in 
the brain (36).
PReDiSPOSinG FACTORS TO CARRY OR 
BOOST nMDAR1-AB
On the basis of these in vitro and in vivo findings, we have to 
assume that basically all naturally occurring NMDAR1-AB 
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have pathogenic potential irrespective of epitope and Ig class. 
This does, however, not mean that the type of Ig class cannot 
initiate distinct cascades of secondary events and thereby 
further shape the ultimate tissue response. But now even more 
questions arise: How can we explain the disease-independent 
high seroprevalence of NMDAR1-AB, increasing with age? 
Do we know of any predisposing factors, and if so, how can 
we integrate their role into the full picture? NMDAR1-AB were 
initially associated with oncological conditions (teratoma) (7). 
Later on, a predisposition to carry these AB was seen upon 
influenza A and B seropositivity, a finding replicated in an 
independent sample (25, 28). Also a genome-wide significant 
genetic marker, rs524991, even related to NMDAR biology, was 
found associated with NMDAR1-AB (28). Whether a leaky BBB, 
causing enhanced exposure of central NMDAR1 to cells of the 
immune system, can induce NMDAR1-AB formation and/or 
boost preexisting specific B cell clones is presently unclear and 
needs to be systematically investigated. Another attractive idea 
that has not yet been pursued in the NMDAR1-AB field is the 
potential modulatory influence of the microbiome on boosting 
of NMDAR1-AB (37).
OTHeR BRAin AnTiGen-DiReCTeD AB
Why do we see NMDAR1-AB so abundantly in health and 
disease? Does this also hold true for other AB directed against 
brain antigens? To address these questions, we analogously 
studied 24 other brain antigen-directed serum AB, previously 
connected with pathological conditions. Again to some sur-
prise, this work revealed comparable frequency, titers, and Ig 
class distribution in healthy and ill subjects. Seroprevalence, 
however, of all of these 24 AB was distinctly lower (<2%) in 
contrast to NMDAR1-AB (up to >20%) (27). Strikingly, the 
predominant Ig class did not depend on health or disease state 
either, but on antigen location, with intracellular epitopes 
predisposing to IgG (27). The equal distribution of these 24 
other AB in health and disease is less astonishing when con-
sidering that multiple brain-directed AB have been reported 
in serum of healthy humans and of different other mammalian 
species (38, 39) as well as abundantly in CSF of encephalitis 
cases (40), even though the respective brain antigens were not 
specified. To sum up, brain antigen-directed AB in general and 
NMDAR1-AB in particular seem to be part of a preexisting 
autoimmune repertoire (37, 41–44) that gains (patho)physi-
ological significance in conditions of intrathecal synthesis or 
compromised BBB, for instance, upon injury, infection, brain 
inflammation, or genetic predisposition to BBB leakiness 
(APOE4 haplotype).
COnCLUSiOnS AnD ReCOMMenDATiOnS
All naturally occurring serum NMDAR1-AB obviously have 
pathogenic potential. For still widely unexplored reasons, they are 
highly frequent (more than other so far identified brain-directed 
AB), and their prevalence clearly increases with age. NMDAR-AB 
seropositivity alone definitely does not justify immunosuppres-
sive treatment. Syndromal relevance of serum NMDAR1-AB 
depends on accessibility to the brain, i.e., BBB permeability. 
Moreover, brain inflammation likely plays a crucial role in 
determining syndrome acuteness and severity as contributed by 
circulating NMDAR1-AB and even more pronounced by respec-
tive plasma cells that reside in or potentially migrate to the brain 
in inflammatory conditions to produce AB intrathecally (40). In 
the inflammatory milieu, they are boosted upon epitope exposure 
and experience class switch to IgG (36). Findings in individuals 
with herpes encephalitis may further support this view (22, 45).
Any underlying encephalitis, be it infectious, lesion induced, 
genetic, or “idiopathic”, may undergo prominent syndrome shap-
ing by the presence of NMDAR1-AB in the sense of “Dalmau’s 
encephalitis” (7–10), which then requires immunosuppressive 
therapy on top of the causal encephalitis treatment (if available). 
Whether intrathecally produced NMDAR1-AB alone, without 
any underlying preexisting inflammation, can cause “Dalmau’s 
encephalitis” remains to be determined. In any case of otherwise 
suspected symptomatic consequences of serum AB directed 
against brain antigens in the absence of overt encephalitis, leaki-
ness of the BBB should be evaluated. Since the albumin quotient 
(employed as clinical approximation to diagnose BBB break-
down) rather indicates blood–CSF barrier disturbance and may 
not always be pathological in mild cases of BBB leakiness (46–48), 
additional determination of BBB disruption (global or local) by 
a novel magnetic resonance imaging (MRI) method (47), which 
can be established as add-on to routine contrast-enhanced MRI, 
may prove helpful for estimating necessity and benefit especially 
of extended immunosuppressive therapeutic interventions.
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